Digoxin immune fab: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 42: Line 42:
*[http://www.rxlist.com/cgi/generic/digoxinfab.htm Digibind description]
*[http://www.rxlist.com/cgi/generic/digoxinfab.htm Digibind description]
*[http://www.fda.gov/cber/label/digpro083101LB.pdf FDA - DigiFab]
*[http://www.fda.gov/cber/label/digpro083101LB.pdf FDA - DigiFab]
{{pharmacology-stub}}
{{Antidotes}}
[[de:Digitalis-Antidot]]
[[de:Digitalis-Antidot]]

Revision as of 14:45, 11 August 2012

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Digoxin immune fab
Clinical data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration		IV infusion, injection
ATC code
Pharmacokinetic data
Elimination half-life15 hours for DigiFab, 23 hours for Digibind
ExcretionRenal
Identifiers
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC6394H9908N1698O2011S58
Molar mass144602.257 g/mol

Overview

Digoxin Immune Fab (Ovine) is the generic name for an antidote for overdose of digitalis.[1] It is made from immunoglobin fragments from sheep who have already been immunized with a digoxin derivative, digoxindicarboxymethoxylamine (DDMA). Its brand names include Digibind and DigiFab, with the former manufactured by GlaxoSmithKline and the latter manufactured by Protherics, Inc.

Pharmacology

It works by binding to the digoxin, rendering them unable to bind to their action sites on target cells. The complexes accumulate in the blood and are expelled by the kidney.

Contraindications

Although no contraindications have been noted, the patient must be closely monitored for anaphylactic shock, and anyone allergic to sheep protein, papain, bromelain, or papaya extracts (papain is used to cleave the antibody into Fab and Fc fragments) should not use Digoxin Immune Fab (Ovine). Because it is relatively new, no drug interaction studies have been performed yet.

References

  1. ↑ DiDomenico RJ, Walton SM, Sanoski CA, Bauman JL (2000). "Analysis of the use of digoxin immune fab for the treatment of non-life-threatening digoxin toxicity". J. Cardiovasc. Pharmacol. Ther. 5 (2): 77–85. PMID 11150387.

External links

de:Digitalis-Antidot

Retrieved from "https://www.wikidoc.org/index.php?title=Digoxin_immune_fab&oldid=681327"